NCT05960565

Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: St. Olavs Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection. The investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.

Detailed description

People with type 1 diabetes will come fasting in the morning to the research facility on two separate days. Both days participants will have a breakfast of their own choice and their regular dose of meal insulin injected. Lyumjev will be used. Frequently collected blood sampled will be analysed for glucose, insulin and glucagon for 3.5 hours. The procedures will be exactly the same both days except that on one of the days they will be randomised to a small dose of glucagon that will be injected at exactly the same site as Lyumjev insulin is injected.

Conditions

• Type 1 Diabetes

Interventions

Type	Name	Description
DRUG	Glucagon	A micro-dose of glucagon is added exactly at the same site as insulin is injected.

Timeline

• Start date: 2023-12-22
• Primary completion: 2023-12-22
• Completion: 2023-12-22
• First posted: 2023-07-25
• Last updated: 2025-06-13

Locations

1 site across 1 country: Norway